Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. Cash Flow Conversion Efficiency
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. cash flow conversion efficiency. Based on the latest financial reports, Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) has a cash flow conversion efficiency ratio of 0.126x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL33.37 Million ≈ $747.36K USD) by net assets (TL263.88 Million ≈ $5.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (2020–2023)
Cash flow conversion efficiency of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. from 2020 to 2023. This chart illustrates how Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Oncosem Onkolojik Sistemler Sanayi ve Ti (ONCSM) stock price for real-time trading data and today's change.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. Cash Flow Conversion Ratio Explained
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. ranked by their cash flow conversion efficiency. Also see ONCSM market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Geospace Technologies Corporation
NASDAQ:GEOS
|
-0.015x |
|
Cenit Co. Ltd
KQ:037760
|
-0.013x |
|
Sukhjit Starch & Chemicals Limited
NSE:SUKHJITS
|
-0.146x |
|
Shareholder Value Beteiligungen AG
XETRA:SVE
|
0.043x |
|
Rapala VMC Oyj
HE:RAP1V
|
-0.006x |
|
TsannKuen (China) Enterprise Co. Ltd
SHE:200512
|
-0.016x |
|
Marygold Companies Inc
NYSE MKT:MGLD
|
-0.040x |
|
Beforepay Group Ltd
AU:B4P
|
-0.080x |
Annual Cash Flow Conversion Efficiency for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. from 2020 to 2023. Review Oncosem Onkolojik Sistemler Sanayi ve Ti free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | TL231.70 Million ≈ $5.19 Million |
TL-38.10 Million ≈ $-853.43K |
-0.164x | -169.94% |
| 2022-12-31 | TL224.08 Million ≈ $5.02 Million |
TL52.69 Million ≈ $1.18 Million |
0.235x | -64.14% |
| 2021-12-31 | TL78.80 Million ≈ $1.76 Million |
TL51.68 Million ≈ $1.16 Million |
0.656x | +156.87% |
| 2020-12-31 | TL76.02 Million ≈ $1.70 Million |
TL19.41 Million ≈ $434.68K |
0.255x | -- |
About Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi manufactures and sells chemotherapy drug preparation kits, medical devices, and test kits in Turkey. The company offers OncoCare Monolitik, an automated chemotherapy drug preparation device; OncoCare Plus, a chemotherapy drug guide; OncoWaste and M-Waste, a hazardous waste sealing system, chemotherapy drugs, cephalosporins, penicillins,… Read more